A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses

Antibody titers that inhibit the influenza virus hemagglutinin (HA) from engaging its receptor are the accepted correlate of protection from infection. Many potent antibodies with broad, intra-subtype specificity bind HA at the receptor binding site (RBS). One barrier to broad H1-H3 cross-subtype ne...

Full description

Saved in:
Bibliographic Details
Published inPLoS biology Vol. 21; no. 12; p. e3002415
Main Authors Simmons, Holly C., Watanabe, Akiko, Oguin III, Thomas H., Van Itallie, Elizabeth S., Wiehe, Kevin J., Sempowski, Gregory D., Kuraoka, Masayuki, Kelsoe, Garnett, McCarthy, Kevin R.
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 21.12.2023
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Antibody titers that inhibit the influenza virus hemagglutinin (HA) from engaging its receptor are the accepted correlate of protection from infection. Many potent antibodies with broad, intra-subtype specificity bind HA at the receptor binding site (RBS). One barrier to broad H1-H3 cross-subtype neutralization is an insertion (133a) between positions 133 and 134 on the rim of the H1 HA RBS. We describe here a class of antibodies that overcomes this barrier. These genetically unrestricted antibodies are abundant in the human B cell memory compartment. Analysis of the affinities of selected members of this class for historical H1 and H3 isolates suggest that they were elicited by H3 exposure and broadened or diverted by later exposure(s) to H1 HA. RBS mutations in egg-adapted vaccine strains cause the new H1 specificity of these antibodies to depend on the egg adaptation. The results suggest that suitable immunogens might elicit 133a-independent, H1-H3 cross neutralization by RBS-directed antibodies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
USDOE Office of Science (SC)
National Institutes of Health (NIH)
AC02-06CH11357; P30 GM124165
Current address: RTI International, Research Triangle Park, North Carolina, United States of America
The authors have declared that no competing interests exist
ISSN:1545-7885
1544-9173
1545-7885
DOI:10.1371/journal.pbio.3002415